BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 24449826)

  • 21. Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastases.
    Tamburrino A; Molinolo AA; Salerno P; Chernock RD; Raffeld M; Xi L; Gutkind JS; Moley JF; Wells SA; Santoro M
    Clin Cancer Res; 2012 Jul; 18(13):3532-40. PubMed ID: 22753663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo.
    Oliveira MN; Hemerly JP; Bastos AU; Tamanaha R; Latini FR; Camacho CP; Impellizzeri A; Maciel RM; Cerutti JM
    Thyroid; 2011 Sep; 21(9):975-85. PubMed ID: 21834681
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RET signals through focal adhesion kinase in medullary thyroid cancer cells.
    Panta GR; Nwariaku F; Kim LT
    Surgery; 2004 Dec; 136(6):1212-7. PubMed ID: 15657578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
    Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
    Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical diagnosis and treatment of familial medullary thyroid carcinoma caused by a p.C618Y RET proto-oncogene mutation in a Chinese pedigree].
    Zhao JQ; Guo L; Qi XP; Chen ZG; Wang KJ; Lou JL; Yu XH; Cheng J; Jin HY; Li XL; Ying RB; Zhang XN
    Zhonghua Yi Xue Za Zhi; 2013 Feb; 93(6):440-4. PubMed ID: 23660264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Y606C RET mutation causes a receptor gain of function.
    Ercolino T; Lombardi A; Becherini L; Piscitelli E; Cantini G; Gaglianò MS; Serio M; Luconi M; Mannelli M
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):253-8. PubMed ID: 18248647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.
    Cote GJ; Evers C; Hu MI; Grubbs EG; Williams MD; Hai T; Duose DY; Houston MR; Bui JH; Mehrotra M; Waguespack SG; Busaidy NL; Cabanillas ME; Habra MA; Luthra R; Sherman SI
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3591-3599. PubMed ID: 28911154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.
    Vitagliano D; De Falco V; Tamburrino A; Coluzzi S; Troncone G; Chiappetta G; Ciardiello F; Tortora G; Fagin JA; Ryan AJ; Carlomagno F; Santoro M
    Endocr Relat Cancer; 2011 Feb; 18(1):1-11. PubMed ID: 20943719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single nucleotide polymorphisms act as modifiers and correlate with the development of medullary and simultaneous medullary/papillary thyroid carcinomas in 2 large, non-related families with the RET V804M proto-oncogene mutation.
    Shifrin AL; Ogilvie JB; Stang MT; Fay AM; Kuo YH; Matulewicz T; Xenachis CZ; Vernick JJ
    Surgery; 2010 Dec; 148(6):1274-80; discussion 1280-1. PubMed ID: 21134561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T.
    Erickson TA; Shih YP; Fass J; Jang M; Tran E
    Thyroid; 2022 Jul; 32(7):789-798. PubMed ID: 35587601
    [No Abstract]   [Full Text] [Related]  

  • 31. Expression of Tenascin C, EGFR, E-Cadherin, and TTF-1 in Medullary Thyroid Carcinoma and the Correlation with RET Mutation Status.
    Steiner F; Hauser-Kronberger C; Rendl G; Rodrigues M; Pirich C
    Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27409604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cofilin is a mediator of RET-promoted medullary thyroid carcinoma cell migration, invasion and proliferation.
    Giardino E; Catalano R; Barbieri AM; Treppiedi D; Mangili F; Spada A; Arosio M; Mantovani G; Peverelli E
    Mol Cell Endocrinol; 2019 Sep; 495():110519. PubMed ID: 31352037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma.
    Ciampi R; Romei C; Cosci B; Vivaldi A; Bottici V; Renzini G; Ugolini C; Tacito A; Basolo F; Pinchera A; Elisei R
    Mol Cell Endocrinol; 2012 Jan; 348(1):176-82. PubMed ID: 21867742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcium-calmodulin-dependent kinase II (CaMKII) mediates insulin-stimulated proliferation and glucose uptake.
    Illario M; Monaco S; Cavallo AL; Esposito I; Formisano P; D'Andrea L; Cipolletta E; Trimarco B; Fenzi G; Rossi G; Vitale M
    Cell Signal; 2009 May; 21(5):786-92. PubMed ID: 19171190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aggressive inherited and sporadic medullary thyroid carcinomas display similar oncogenic pathways.
    Ameur N; Lacroix L; Roucan S; Roux V; Broutin S; Talbot M; Dupuy C; Caillou B; Schlumberger M; Bidart JM
    Endocr Relat Cancer; 2009 Dec; 16(4):1261-72. PubMed ID: 19675075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Novel Germline Deletion of p.C630 in RET Causes MTC and Promotes Cell Proliferation and Sensitivity to Pralsetinib.
    Ma X; Ma X; Chin L; Zhu Z; Han H
    J Clin Endocrinol Metab; 2022 Aug; 107(9):2636-2643. PubMed ID: 35689816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RET Regulates Human Medullary Thyroid Cancer Cell Proliferation through CDK5 and STAT3 Activation.
    Yue CH; Oner M; Chiu CY; Chen MC; Teng CL; Wang HY; Hsieh JT; Lai CH; Lin H
    Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34207842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants.
    Yang J; Chen K; Zhang G; Yang QY; Li YS; Huang SZ; Wang YL; Yang W; Jiang XJ; Yan HX; Zhu JQ; Xiang R; Luo YF; Li WM; Wei YQ; Li LL; Yang SY
    Eur J Med Chem; 2018 Jan; 143():1148-1164. PubMed ID: 29133048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.
    Verbeek HH; Alves MM; de Groot JW; Osinga J; Plukker JT; Links TP; Hofstra RM
    J Clin Endocrinol Metab; 2011 Jun; 96(6):E991-5. PubMed ID: 21470995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.